2Q approvals
By BC Staff | Jul 5, 2010 | 7:00 AM GMT
2Q approvals
| Company | Approvals |
| Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) | Japan approves Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH) |
| Amgen Inc. (NASDAQ:AMGN) | FDA approves Prolia denosumab to treat osteoporosis in postmenopausal women whoare at high risk of fractures or have failed or are intolerant to other osteoporosis therapy; EC approves Prolia to treat osteoporosis in postmenopausal women and to treat bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures |
| BioAlliance Pharma S.A. (Euronext:BIO) | FDA approves Oravig miconazole to treat oropharyngeal candidiasis |
| Celgene Corp. (NASDAQ:CELG) | Japan approves Revlimid lenalidomide in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM) |
| Cipher Pharmaceuticals Inc. (TSX:DND) | FDA approves Cip-tramadol ER to treat moderate to moderately severe chronic pain |
| Dendreon Corp. (NASDAQ:DNDN) | FDA approves Provenge sipuleucel-T to treat metastatic castrate-resistant prostate cancer |
| Genmab A/S (CSE:GEN)/ | EC grants conditional approval for Arzerra ofatumumab to treat chronic lymphocytic |
| GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)
|
Read the full 1698 word article
